<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138415">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299168</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC-001</org_study_id>
    <nct_id>NCT01299168</nct_id>
  </id_info>
  <brief_title>Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation</brief_title>
  <official_title>Multi-centric Observational Study to Analyse the Diagnostic Molecular Features in the Clinical Setting of Kidney Allograft Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard for biopsy-based diagnoses of dysfunction of kidney transplants is the
      Banff Classification which represents arbitrary international consensus. Recent data-driven
      approaches using molecular and conventional technologies indicate that mere consensus
      produces frequently incorrect diagnoses with potential harm to patients due to inappropriate
      treatment. To address this unmet need and improve diagnostics in the area of organ
      transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC) has developed a new
      diagnostic system that combines the molecular and histopathological features of transplant
      biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic
      System. The present study will validate and refine this system in 500 prospectively
      unselected biopsies for clinical indications from American, Canadian and European centres in
      addition to 300 biopsies already collected. Thus this is the extension of the INTERCOM study
      (INTERCOMEX). In addition to demonstrating the feasibility and value of this System in
      routine patient care and clinical trials, the study will develop and optimize a transparent
      and user-friendly reporting format to communicate this information to clinicians and obtain
      detailed feedback on how this system can best improve patient care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is now enrolling (N=800) and the results are being analyzed for the first 300
      collected biopsies. Follow-up data is, and will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validate the Integrated Diagnostic System in the International Collaborative Microarray (INTERCOM) Study</measure>
    <time_frame>2013-2016</time_frame>
    <description>The rejection classifier predicts Banff diagnosis of any rejection: ABMR, TCMR, or mixed ABMR and TCMR;
The TCMR classifier predicts the presence of Banff TCMR lesions/diagnoses;
The ABMR classifier predicts the presence of ABMR lesions;
In late (&gt;1yr) biopsies for clinical indications, the failure classifier predicts failure within three years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate the feasibility of molecular phenotyping of 300 + 500 kidney transplant biopsies for clinical indications.</measure>
    <time_frame>2014-2016</time_frame>
    <description>To test the hypothesis that the molecular phenotype of a newly acquired sample predicts the histologic and clinical features of this sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate the feasibility of molecular phenotyping of 500 biopsies in real time i.e. returning the molecular phenotyping report in two working days upon sample arrival.</measure>
    <time_frame>2015-2016</time_frame>
    <description>Refine the reports based on feedback from the participants.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Validation Study of Molecular Diagnostic System</condition>
  <condition>Development of Reporting System for Molecular Diagnosis</condition>
  <condition>Incorporate Molecular Diagnosis Into Diagnostic Standards</condition>
  <arm_group>
    <arm_group_label>Kidney Transplant Biopsies for Cause</arm_group_label>
    <description>The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Needle kidney biopsy core as per local standard of care
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients with a functioning kidney transplant undergoing a
        biopsy for clinicalindications as standard of care to determine the cause of their graft
        dysfunction (deterioration in graft function, delayed graft function, proteinuria).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All kidney transplant recipients â‰¥18yrs of age undergoing a kidney biopsy for
             clinical indications, as determined by their physician or surgeon, will be eligible
             to enrol in the study.

        Exclusion Criteria:

          -  Patients will be excluded from the study if they decline participation or are unable
             to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip F Halloran, MD PhD</last_name>
    <phone>1 780 492-6160</phone>
    <email>phallora@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konrad S Famulski, PhD DSc</last_name>
    <phone>1 780 4921725</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Bartosic</last_name>
      <email>abartosic@smail.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Bromoberg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matt Weir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>MI 48109-5395</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyssa Wiegand</last_name>
      <phone>734-771-9819</phone>
      <email>elyssaw@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Darlene McLean</last_name>
      <email>darkons@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Milagros D Samaniego-Picota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>MO 63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Andrew Malone, MD</last_name>
      <phone>314-362-8351</phone>
      <email>amalone@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Transplant Associates</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Kratzer</last_name>
      <email>pkratzer@pinnaclehealth.org</email>
    </contact>
    <investigator>
      <last_name>Harold Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seth C Narins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute - Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Carreon</last_name>
      <email>gloria.carreon@mhshealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Sherri Shade</last_name>
      <email>sherri.shade@mhshealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>. Adam Bingaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University School of Medicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaurav Gupta, MD</last_name>
      <email>ggupta@mcvh-vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Baldecchi</last_name>
      <email>mbaldecchi@mcvh-vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gaurav Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>WI 53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Boehmig, MD PhD</last_name>
      <email>georg.boehmig@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Farsad Eskandry, MD</last_name>
      <email>farsad.eskandary@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Georg Boehmig, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farsad Eskandry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital St. Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CharitÃ© - UniversitÃ¤tmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016 Sep;12(9):534-48. doi: 10.1038/nrneph.2016.85. Epub 2016 Jun 27. Review.</citation>
    <PMID>27345248</PMID>
  </reference>
  <results_reference>
    <citation>Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, SerÃ³n D, SellarÃ©s J, Einecke G, Reeve J. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant. 2013 Sep;13(9):2352-63. doi: 10.1111/ajt.12387. Epub 2013 Aug 5.</citation>
    <PMID>23915426</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, SerÃ³n D, SellarÃ©s J, Einecke G, Reeve J. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am J Transplant. 2013 Nov;13(11):2865-74. doi: 10.1111/ajt.12465. Epub 2013 Oct 3.</citation>
    <PMID>24119109</PMID>
  </results_reference>
  <results_reference>
    <citation>Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2014 Oct;25(10):2267-77. doi: 10.1681/ASN.2013111149. Epub 2014 Apr 3.</citation>
    <PMID>24700874</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar ID, Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, SerÃ³n D, SellarÃ©s J, Einecke G, Reeve J. Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol. 2015 Jul;26(7):1711-20. doi: 10.1681/ASN.2014060588. Epub 2014 Nov 6.</citation>
    <PMID>25377077</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Merino Lopez M, Barreto Pereira A. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants. Am J Transplant. 2016 Mar;16(3):908-20. doi: 10.1111/ajt.13551. Epub 2016 Jan 6.</citation>
    <PMID>26743766</PMID>
  </results_reference>
  <results_reference>
    <citation>Reeve J, Chang J, Salazar ID, Lopez MM, Halloran PF. Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection. Am J Transplant. 2016 Apr;16(4):1183-92. doi: 10.1111/ajt.13572. Epub 2016 Jan 5.</citation>
    <PMID>26730747</PMID>
  </results_reference>
  <results_reference>
    <citation>Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, KikiÄ‡ Å½, Haslacher H, Rasoul-Rockenschaub S, Kaltenecker CC, KÃ¶nig F, Hidalgo LG, Oberbauer R, Halloran PF, BÃ¶hmig GA. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Transplantation. 2017 Mar;101(3):631-641. doi: 10.1097/TP.0000000000001195.</citation>
    <PMID>27120452</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>February 16, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Philip Halloran</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>global gene expression</keyword>
  <keyword>molecular diagnostic classifiers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
